Jessica C Garbern
Overview
Explore the profile of Jessica C Garbern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Velayutham N, Garbern J, Elwell H, Zhuo Z, Ruland L, Elcure Alvarez F, et al.
J Am Heart Assoc
. 2024 Jun;
13(13):e033155.
PMID: 38934864
Background: Current protocols generate highly pure human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in vitro that recapitulate characteristics of mature in vivo cardiomyocytes. Yet, a risk of arrhythmias exists when...
2.
Lin Z, Garbern J, Liu R, Li Q, Mancheno Juncosa E, Elwell H, et al.
Sci Adv
. 2023 Mar;
9(10):eade8513.
PMID: 36888704
Clinical translation of stem cell therapies for heart disease requires electrical integration of transplanted cardiomyocytes. Generation of electrically matured human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is critical for electrical...
3.
Garbern J, Lee R
Dev Cell
. 2022 Mar;
57(4):424-439.
PMID: 35231426
Cardiovascular disease is a leading cause of death worldwide, and thus there remains great interest in regenerative approaches to treat heart failure. In the past 20 years, the field of...
4.
Chen M, Lee R, Garbern J
Cardiovasc Res
. 2021 May;
118(5):1173-1187.
PMID: 33963378
Cellular senescence is a state of irreversible cell cycle arrest associated with ageing. Senescence of different cardiac cell types can direct the pathophysiology of cardiovascular diseases (CVDs) such as atherosclerosis,...
5.
Garbern J, Lee R
Stem Cell Res Ther
. 2021 Mar;
12(1):177.
PMID: 33712058
Current methods to differentiate cardiomyocytes from human pluripotent stem cells (PSCs) inadequately recapitulate complete development and result in PSC-derived cardiomyocytes (PSC-CMs) with an immature or fetal-like phenotype. Embryonic and fetal...
6.
Sarikhani M, Garbern J, Ma S, Sereda R, Conde J, Krahenbuhl G, et al.
Stem Cell Reports
. 2020 Jul;
15(2):498-514.
PMID: 32649901
Recent studies suggest that metabolic regulation may improve differentiation of cardiomyocytes derived from induced pluripotent stem cells (iPSCs). AMP-activated protein kinase (AMPK) is a master regulator of metabolic activities. We...
7.
Garbern J, Escalante G, Lee R
Trends Cardiovasc Med
. 2020 Jan;
31(2):85-90.
PMID: 31983535
Today, cell replacement therapy using pluripotent stem cell-derived cardiomyocytes (PSC-CMs) remains a research endeavor, with several hurdles that must be overcome before delivery of PSC-CMs can become a therapeutic reality....
8.
Garbern J, Helman A, Sereda R, Sarikhani M, Ahmed A, Escalante G, et al.
Circulation
. 2019 Nov;
141(4):285-300.
PMID: 31707831
Background: Current differentiation protocols to produce cardiomyocytes from human induced pluripotent stem cells (iPSCs) are capable of generating highly pure cardiomyocyte populations as determined by expression of cardiac troponin T....
9.
Asimacopoulos E, Garbern J, Gauvreau K, Blume E, Daly K, Singh T
Transplantation
. 2019 Oct;
104(1):e31-e37.
PMID: 31568274
Background: Two or more early rejections (<1 y) or any late acute rejection (>1 y) have been associated with coronary artery vasculopathy (CAV) in pediatric heart transplant (HT) recipients. We...
10.
Goldstein J, Sengul H, Messemer K, Fernandez-Alfara M, Garbern J, Kristl A, et al.
Blood
. 2019 Sep;
134(20):1712-1716.
PMID: 31530563
Tightly regulated production of mature blood cells is essential for health and survival in vertebrates and dependent on discrete populations of blood-forming (hematopoietic) stem and progenitor cells. Prior studies suggested...